Introduction
============

Bovine tuberculosis (BTB) is caused by the intracellular pathogen *Mycobacterium bovis* (*M. bovis*), which is a facultative intracellular parasite of macrophages. BTB has a significant economic impact and serious implications for human health, particularly in developing countries ([@b1-etm-0-0-2814]). *M. bovis* can be transmitted to humans by infectious bacilli via respiratory contact with infected cattle, or consumption of unpasteurized dairy products ([@b2-etm-0-0-2814]). The host immune response to *M. bovis* infection is complex: Following initial exposure, T-helper cell-1 (T~h~1) innate immunity is induced. The bacilli are phagocytosed by host macrophages via pathogen-recognition receptors (PRRs), such as Toll-like receptors (TLRs) and C-type lectin receptors ([@b3-etm-0-0-2814],[@b4-etm-0-0-2814]). Signals transduced through these receptors result in the release of endogenous cytokines, which initiate the T-cell secretion of proinflammatory cytokines, including tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ). The action of IFN-γ on infected macrophages promotes granuloma formation, which prevents the spread of infection ([@b5-etm-0-0-2814]). However, the pathogen often persists within granulomas, and this latent infection can recur as active tuberculosis. The mechanisms underlying evasion of the host immune response by *M. bovis* are not entirely understood; however they are known to involve the prevention of host phagosome maturation, the inhibition of apoptosis in infected macrophages, and the suppression of cell signaling pathways and cytokine production ([@b6-etm-0-0-2814]--[@b8-etm-0-0-2814]).

Genomic technologies can be used to elucidate the molecular mechanisms underlying immune responses to pathogens. With the availability of the complete *Bos taurus* genome ([@b9-etm-0-0-2814]), numerous studies have used bovine genome microarrays to analyze transcriptional changes induced by infection of various types of bovine cells with *M. bovis* ([@b10-etm-0-0-2814],[@b11-etm-0-0-2814]). Killick *et al* ([@b12-etm-0-0-2814]) reported that *M. bovis* infection of peripheral blood leukocytes was associated with decreased expression levels of numerous host genes. Using an Affymetrix bovine genome array to investigate the effects of *M. bovis* challenge on bovine monocyte-derived macrophages *in vitro*, Magee *et al* ([@b6-etm-0-0-2814]) observed significant alterations in expression of genes associated with the inflammatory response, and cell signaling pathways, including TLRs, PRRs and apoptosis. Furthermore, the suppression of immune-associated genes has been detected *in vivo* in *M. bovis*-infected cattle ([@b10-etm-0-0-2814]).

These observations strongly suggest that *M. bovis* evades immune surveillance by altering the expression of genes essential to host immunity. The timing and potency of the cellular and immunological events that occur immediately after infection are suggested to be crucial determinants governing the outcome of an infection ([@b13-etm-0-0-2814]). Therefore, further elucidation of these early events in numerous types of host cells is essential for the prevention, detection, and treatment of *M. bovis* infections. The aim of the present study was to evaluate early changes in global gene expression in bovine peripheral blood mononuclear cells (PBMCs) in response to *M. bovis* exposure. Microarray analyses were used to compare PBMC gene expression over a time course of 0, 4, and 24 h following exposure to *M. bovis.* Systems analysis was then used to determine the pathways and networks associated with the affected genes.

Materials and methods
=====================

### PBMC preparation

The three 3-year-old female Holstein cattle with no recent history of BTB, which were used in the present study, were obtained from the National Taiwan University Experimental Farm (Taipei, Taiwan, R.O.C). The cattle were maintained under uniform housing conditions (temperature, 25--28°C; humidity, 50--70%) and nutritional regimens; the cattle were fed twice a day with alfalfa and pangola grass hay and fresh, farm-grown grass, and all tested negative on tuberculin skin tests. All procedures described in the present study were reviewed and approved by the National Taiwan University Institutional Animal Care and Use Committee (Taipei, Taiwan, R.O.C). From each animal, 50 ml blood from the vein was collected in a sterile heparinized bottle and layered onto ACCUSPIN™ tubes containing Histopaque® 1077 (Sigma-Aldrich, St. Louis, MO, USA). Following density gradient centrifugation (300 × g for 20 min at room temperature), the PBMCs were collected and cultured as previously described by Magee *et al* ([@b6-etm-0-0-2814]), with numerous modifications, including the use of an antibiotic-free culture media supplemented with NaHCO~3~ and 10% fetal bovine serum. Cell cultures in 60 mm dishes (\~5×10^6^ cells/dish), were grown in RPMI (Gibco Life Technologies, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (GE Healthcare Life Sciences, Logan, UT, USA) and NaHCO~3~ to a final concentration of 26 mM at 37°C for 24 h in a culture incubator containing 5% CO~2~. The medium was then replaced with 1 ml fresh medium in order to remove any non-adherent cells. To ensure that the same number of PBMCs were subjected to M. bovis-challenge, 80--100% confluent monolayers of PBMCs were generated and counted on day 3, yielding \~5×10^6^ cells per dishes, providing enough total RNA for microarray analysis. The cells were counted in Marienfeld® Thoma counting chamber (Celeromics Technologies, Grenoble, France), and trypan blue solution (Sigma-Aldrich, St. Luis, MO, USA) was used for the exclusion of dead cells.

### Bacterial preparations

M. bovis strain 331-A1 (Animal Health Research Institute, New Taipei City, Taiwan, R.O.C), which was isolated in 2008 from cattle with tuberculosis, was used. The strain was confirmed by acid-fast staining using the Ziehl-Neelsen method, the gold standard procedure for the diagnosis of tuberculosis, and identified in mycobacterium culture by PCR and spoligotyping ([@b14-etm-0-0-2814]). The strain used was spoligotype SB0265, which is frequently isolated from cattle in Taiwan. The strain was cultured in Middlebrook 7H9 broth (BD Biosciences, Franklin Lakes, NJ, USA) containing 10% (v/v) Middlebrook albumin-dextrose-catalase (BD Biosciences), 0.05% Tween 80 (Sigma-Aldrich) and 0.40% (w/v) sodium pyruvate (Sigma-Aldrich) at 37°C. Bacterial suspensions were then centrifuged at 3,000 × g for 15 min at 25°C, and the pellets were washed twice in phosphate-buffered saline (PBS, pH 7.0), and resuspended in PBS prior to the determination of bacterial concentrations. A NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, Inc., Wilmington, DE, USA) was used to determine the optical density of the bacterial culture and calculate bacterial concentration in colony-forming u/ml. The concentration of the bacterial inoculum was 10^7^ colony-forming units/ml. Fresh stocks of bacteria were prepared for each experiment.

### In vitro challenge of PBMCs with M. bovis

When the PBMCs reached 80% confluence, three dishes for each M. bovis infection trial were randomly selected from the 20 dishes grown from cells collected from each cow. All *in vitro* challenge experiments included a non-challenge PBMC control for each time point. The cells were inoculated at a multiplicity of infection (MOI) of \~2:1 ([@b6-etm-0-0-2814]), and control cultures were treated in the same manner using PBS instead of bacterial suspensions. Inoculated and control cultures were incubated for either 4 h (4-hours post-infection (hpi) group) or 24 h (24-hpi group). Total RNA was then extracted using the RNeasy Mini kit (Qiagen, Inc., Valencia, CA, USA), according to the manufacturer\'s instructions. The concentration and purity of RNA extracts were verified optically using a spectrophotometer (ND-1000; Nanodrop Technologies, Thermo Fisher Scientific, Inc.) and the Bioanalyzer 2100 (Agilent Technologies, Inc., Santa Clara, CA, USA), respectively.

### Microarray analysis

Bovine V2 Oligo 4×44 K microarrays (Agilent Technologies, Inc.) were used to determine the differential gene expression between infected and control cells. For reverse transcription, second-strand cDNA was synthesized from 0.5 µg total RNA using the Fluorescent Linear Amplification kit containing T7 RNA polymerase (Agilent Technologies, Inc.). The cDNA served as template for *in vitro* transcription to produce target cRNA labeled with Cy3-CTP (to label infected cells) and Cy5-CTP (to label control cells) (PerkinElmer, Inc., Waltham, MA, USA). Labeled cRNA (0.825 µg) was fragmented (mean size, \~50--100 nucleotides) in fragmentation buffer (Agilent Technologies, Inc.) at 60°C for 30 min. The prepared cRNA was subsequently hybridized to the microarray at 60°C for 17 h. Two replicates of the microarray assays (M1 and M2) were performed. Hybridized microarray chips were scanned using the Agilent Microarray Scanner with Feature Extraction software 9.5.3 (Agilent Technologies, Inc.). The locally weighted linear regression method was applied to normalize the results by rank consistency filtering.

### Statistical analysis of microarray data

Microarray data were analyzed using GeneSpring GX 7.3.1 software (Agilent Technologies, Inc.). With a false discovery rate \<0.05, data acquisition was conducted using the following criteria: i) P\<0.01 for gene expression difference (GeneSpring); ii) a distinct signal from the microarray image that was flagged by the software; and iii) \|-log 2-fold change\| ≥2.5. Significantly enriched genes were identified using the Kyoto Encyclopedia of Genes and Genomes (KEGG; <http://www.genome.jp/kegg/>), and the pathways and networks involving these genes were identified using Ingenuity Pathway Analysis (IPA; <http://norris.usc.libguides.com/IPA>), a web-based functional analysis tool. The criteria for gene selection for IPA analysis were as follows: i) A fold-change in expression \>2 for comparison between 0 and 4 hpi and \>4 for comparison between 0 and 24 hpi, and ii) P\<0.05 for changes in gene expression in cells from all three cows.

Results
=======

### Kinetics of gene expression during M. bovis infection

Comprehensive gene expression profiles of the three PBMC samples with or without M. bovis challenge were generated using oligonucleotide bovine microarrays containing 43,803 probe sets. These probe sets interrogated the expression levels of \~29,356 transcripts, some of which mapped to known genes. A total of 3,937 probe sets passed the filtering step, consisting of a t-test with an adjusted P-value threshold ≤0.05. At 4 and 24 hpi, 207 and 3,186 unique probe sets, respectively, were significantly differentially expressed ([Fig. 1](#f1-etm-0-0-2814){ref-type="fig"}). To investigate the kinetics of gene expression, a total of 420 genes (including genes of unknown function) were found to be differentially expressed. Genes with an upregulated expression (30 out of 135 genes of known function) following exposure of PBMC to *M. bovis* are listed in [Table I](#tI-etm-0-0-2814){ref-type="table"}, and those with a downregulated expression (84 out of 285 genes of known function) are listed in [Table II](#tII-etm-0-0-2814){ref-type="table"}. As shown in [Tables I](#tI-etm-0-0-2814){ref-type="table"} and [II](#tII-etm-0-0-2814){ref-type="table"}, the genes with a fold change ≥2.5 between 0--4, 4--24 and 0--24 h were listed and divided by functions. Inspection of KEGG pathway annotations for these genes detected their association with the immune system (28%), signal transduction (23%), metabolism (21%), transport and catabolism (8%), genetic information processing (6%), cell growth and death (6%), and other organismal systems (8%). Of the affected genes associated with the immune system, 84.85% were downregulated in PBMCs following M. bovis challenge ([Fig. 2](#f2-etm-0-0-2814){ref-type="fig"}). These results indicate a decreased T~h~1 response \[downregulated TNF-α, IFN-γ, and interleukin (IL)-12β\], suggesting M. bovis infection may suppress the PBMC immune response.

### Identification of pathways and networks associated with genes affected by M. bovis infection

Gene set enrichment analysis was performed on the microarray data to identify the specific biological pathways associated with genes differentially expressed upon M. bovis infection. IPA of the microarray data identified the functional profiles of 15 genes that were differentially expressed between 0 and 4 hpi ([Table III](#tIII-etm-0-0-2814){ref-type="table"}), and their associated pathways ([Table IV](#tIV-etm-0-0-2814){ref-type="table"}). A total of 91 genes with differential expression between 0 and 24 hpi were selected in the present study for IPA; and the results of the top 28 (greatest change in expression) are shown in [Table V](#tV-etm-0-0-2814){ref-type="table"}. The pathways associated with these genes are shown in [Table VI](#tVI-etm-0-0-2814){ref-type="table"}. A map of the network of pathways involving genes differentially expressed between 0 and 4 hpi is shown in [Figs. 3](#f3-etm-0-0-2814){ref-type="fig"}--[6](#f6-etm-0-0-2814){ref-type="fig"}.

The key genes in network 1 ([Fig. 3](#f3-etm-0-0-2814){ref-type="fig"}) were transforming growth factor-β and matrix metalloproteinase (MMP)13; both of which are major genes associated with inflammatory responses. There were only two genes in network 2 ([Fig. 4](#f4-etm-0-0-2814){ref-type="fig"}): Retinol-binding protein 4 and adenylyl cyclase 6; both of which have known roles in development, particularly embryonic, skeletal and muscular, and so were unlikely to be associated with infection. The key gene in network 3 ([Fig. 5](#f5-etm-0-0-2814){ref-type="fig"}) was claudin 3 (CLDN3); as in the case of network 2, this network is predominantly associated with skeletal and muscular development, and therefore has only a weak association with the infection. The key gene in network 4 ([Fig. 6](#f6-etm-0-0-2814){ref-type="fig"}) was gem-associated protein 7, which is associated with cell death and survival, and therefore may be associated with the late response to *M. bovis* infection. The four networks of the pathways comprising genes differentially expressed between 0 and 24 hpi are shown in [Figs. 7](#f7-etm-0-0-2814){ref-type="fig"}--[10](#f10-etm-0-0-2814){ref-type="fig"}. The key gene in network 1 was TNF-α, which interacts with IFN-γ, MMP13, and thrombospondin 1 (THBS1) ([Fig. 7](#f7-etm-0-0-2814){ref-type="fig"}). Expression of these four genes was downregulated. TNF-α also interacts with IL-17 receptor B and thrombomodulin, both of which demonstrated downregulated expression. In addition, TNF-α interacts with activating protein-1, which upregulates complement component 3a receptor 1. The key genes in network 2 were luteinizing hormone (LH) and IL-13. IL-13 upregulates C-type lectin domain family 4 member E, and glycoprotein (transmembrane) nmb, and downregulates THBS1 and androgen-induced 1 ([Fig. 8](#f8-etm-0-0-2814){ref-type="fig"}). The key gene in network 3 was IFN-γ, which regulates the expression of B-cell lymphoma-2 and the nuclear factor (NF)-κB p65 subunit ([Fig. 9](#f9-etm-0-0-2814){ref-type="fig"}). The key gene in network 4 was Akt, which regulates the expression of NF-κB, followed by the downregulation of CCAAT/enhancer binding protein, delta ([Fig. 10](#f10-etm-0-0-2814){ref-type="fig"}).

Discussion
==========

The present study demonstrated that bovine PBMCs responded to *in vitro M. bovis* infection by undergoing large-scale alterations in gene expression. The expression of 420 genes was shown to significantly differ between 4 and 24 hpi, with 135 upregulated and 285 downregulated genes. Inspection of KEGG pathway annotations for these genes demonstrated that the majority was associated with the immune system, signal transduction, and metabolism. Of the affected genes with immune system functions, 84.85% were downregulated. System pathway analysis of differentially expressed genes revealed the key genes in four different networks to be TNF-α, IFN-γ, LH, IL-13, and NF-κB. These results suggested that *M. bovis* may suppress the PBMC immune response soon after infection.

The number of differentially expressed PBMC genes increased during the first 24 h following exposure to *M. bovis*. Changes were observed in 207 unique probe sets at 4 hpi and in 3,186 unique probe sets at 24 hpi. Of these, 420 genes displayed significantly altered expression from 4 to 24 hpi, with expression decreasing for 285 genes and increasing for 135 genes. In addition, the fold-change in expression of the downregulated genes was much greater, as compared with that of upregulated genes. Previous studies of transcriptional responses to *M. bovis* infection have reported downregulation of the majority of differentially expressed genes ([@b10-etm-0-0-2814],[@b12-etm-0-0-2814],[@b15-etm-0-0-2814],[@b16-etm-0-0-2814]). In the present study, more genes were suppressed later post-infection (24 h), as compared with earlier (4 h), suggesting the cellular activities involving these genes progressively declined during *M. bovis* infection.

Inspection of KEGG pathway annotations for the 420 differentially expressed genes revealed their involvement in the immune system (28%), signal transduction (23%), metabolism (21%), transport and catabolism (8%), genetic information processing (6%), cell growth and death (6%), and other organismal systems (8%). Of these genes, \>67% (280) exhibited time-dependent decreases in expression associated with signal transduction, immune response, pro-inflammatory cytokines, metabolism, or cell death processes. In addition, 84.85% of the differentially expressed genes associated with immune responses displayed downregulated expression in infected PBMCs. Suppression of host immune response genes is a common finding among studies of gene expression following *M. bovis* infection ([@b6-etm-0-0-2814],[@b12-etm-0-0-2814],[@b16-etm-0-0-2814]). Transcriptome analysis of peripheral blood leukocytes from cattle infected with *M. bovis* previously detected over-representation of differentially expressed genes associated with the immune response; of these genes, 64.5% showed decreased expression, indicating *M. bovis* infection may be associated with the suppression of host immune genes ([@b12-etm-0-0-2814]). Meade *et al* ([@b16-etm-0-0-2814]) reported a decrease in the *in vivo* PBMC expression of key innate immune genes in *M. bovis*-infected cattle. Subsequent *in vivo* transcriptional studies of *M. bovis*-infected cattle demonstrated that PBMC genes associated with immunity, inflammatory responses, and apoptosis were among those with the highest differential expression ([@b10-etm-0-0-2814]). These *in vivo* experiments were conducted in animals following the establishment of an infection, ranging from 2--12 months following inoculation. The *in vitro* data of the present study supports these findings and further reveals that changes in gene expression begin very early in the course of infection.

Notably, *M. bovis* infection resulted in a decrease in expression of the most important components of the T~h~1 response: IFN-γ, TNF-α, and IL-12. The significance of the altered expression of IFN-γ and TNF-α is demonstrated by their mapping to key locations in the pathway networks. These genes are crucial to the host immune response against mycobacteria, including granuloma formation and apoptosis. Signaling via the IFN-γ pathway is required for macrophage activation and granuloma formation ([@b5-etm-0-0-2814]). Such signaling is dependent on the production of IFN-γ by T-cells; and IFN-γ synthesis requires the cytokine IL-12. Conversely, the observation in the present study of decreased IFN-γ expression differs from a previous study, which reported that the vaccine *Mycobacterium bovis* bacillus Calmette-Guérin triggers a T~h~1-type response ([@b17-etm-0-0-2814]). In addition, another study reported the increased expression of IFN-γ in PBMC from cattle infected 4 months previously ([@b10-etm-0-0-2814]). However, these studies observed that genes downstream of IFN-γ were significantly downregulated, suggesting suppression of IFN-γ signaling despite its increased expression. Strain virulence, MOI, cell type, post-infection harvest time, and specific assays used may also underlie these different results.

Apoptosis of infected macrophages is an innate host defense mechanism against intracellular *M. bovis* and *M. tuberculosis.* The extrinsic cell death pathway involved in apoptosis is induced by the binding of TNF-α to its receptor on the macrophage surface. Macrophages infected with attenuated strains of pathogenic mycobacteria undergo TNF-α-mediated apoptosis, reducing the viability of intracellular bacilli. Virulent *M. tuberculosis* strains have been found to suppress macrophage apoptosis ([@b18-etm-0-0-2814],[@b19-etm-0-0-2814]). Previous studies have detected upregulation of programmed cell death signaling genes, including TNF-α, following live *M. bovis* challenge of bovine macrophages *in vitro* ([@b6-etm-0-0-2814],[@b20-etm-0-0-2814]). Therefore, it is intriguing that TNF-α was the key gene affected in network 1. Through this network of pathways, TNF-α was shown to interact with IFN-γ, MMP13, and THBS1.

The present study has numerous limitations. The methods did not distinguish between *M. bovis*-infected cells and *M. bovis*-exposed cells; therefore, no correlations can be made between gene expression levels and infection rates. The *M. bovis* cells were not from a standard strain; therefore, some comparisons to other studies may be less reliable. In addition, the present study does not provide further analysis of specific genes indicated by the microarray data. However, the data from this preliminary screening provide a solid foundation for future investigations.

To the best of our knowledge, this is the first study providing a time-course analysis of global gene expression in bovine PBMCs following *in vitro* exposure to *M. bovis*. Our data indicate that extensive alterations in PBMC gene expression may begin early in infection. The majority of the differentially expressed genes were related to immune responses and cell survival. Changes observed in the expression of genes associated with immune responses suggest that *M. bovis* infection may be associated with the suppression of immune response-related gene expression. In addition, *M. bovis* infection in PBMCs may suppress apoptosis by interfering with TNF-α signaling. The present study provides valuable information for the further characterization of host responses to *M. bovis* infection.

The present study was supported by a grant from the Centers for Disease Control, Taiwan, the Republic of China.
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###### 

Genes with upregulated expression (≥2.5-fold) following exposure of peripheral blood mononuclear cells to Mycobacterium bovis.

                                            Fold change                            
  ---------------------------- ------------ ------------- ------- ------ --------- ------------------------------------------------------------
  Signal transduction                                                              
                               CLEC4E       1.15          7.70    8.85   0.001     C-type lectin domain family 4 member E
                               STAT1        0.71          2.98    2.12   0.002     Signal transducer and activator of transcription 1
                               DDIT3        0.78          2.91    2.27   0.004     DNA-damage-inducible transcript 3
                               LDHA         0.77          2.81    2.16   \<0.001   Lactate dehydrogenase A (LDHA)
  Immune system                                                                    
                               C3AR1        0.97          6.68    6.49   0.002     Complement component 3a receptor 1
                               PDK1         0.86          6.14    5.26   0.001     Pyruvate dehydrogenase kinase, isozyme 1
                               DAPP1        0.58          4.16    2.43   \<0.001   Dual adaptor of phosphotyrosine and 3-phosphoinositides
                               RASGRP1      0.90          3.43    3.09   \<0.001   RAS guanyl releasing protein 1 (calcium and DAG-regulated)
                               CD244        0.94          3.29    3.08   \<0.001   CD244 molecule, natural killer cell receptor 2B4
                               IL7          0.61          2.63    1.59   0.001     Interleukin-7 precursor
  Endocytosis and transport                                                        
                               COLEC11      1.14          4.78    5.44   \<0.001   Collectin sub-family member 11
                               LAMP3        0.97          2.81    2.72   0.001     Lysosomal-associated membrane protein 3
                               CTSL2        0.39          2.78    1.08   0.005     Cathepsin L2
                               EHD1         0.90          2.58    2.33   0.001     EH-domain containing 1
  Inflammation and apoptosis                                                       
                               CDKN2D       1.21          03.15   3.82   \<0.001   Cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4)
                               CCNG2        0.59          2.60    1.53   0.004     Cyclin G2
  Others                                                                           
                               ME1          0.95          6.79    6.48   0.002     Malic enzyme 1
                               FBXL3        0.90          4.21    3.80   \<0.001   F-box and leucine-rich repeat protein 3
                               SQLE         0.97          3.52    3.41   0.003     Squalene epoxidase
                               POLD4        1.01          3.34    3.37   0.003     Polymerase (DNA-directed), delta 4
                               PTGES        1.12          3.13    3.52   \<0.001   Prostaglandin E synthase (PTGES)
                               PHOSPHO2     1.03          3.06    3.15   \<0.001   Phosphatase, orphan 2
                               DCK          1.03          2.99    3.07   \<0.001   Deoxycytidine kinase
                               PLA2G16      0.84          2.91    2.44   \<0.001   Phospholipase A2, group XVI
                               CSGALNACT1   1.07          2.87    3.07   0.001     Chondroitisulfate N-acetylgalactosam inyltransferase 1
                               NAPB         0.85          2.83    2.40   0.005     N-ethylmaleimide-sensitive factor attachment protein, beta
                               PGAP1        1.00          2.77    2.76   \<0.001   Similar to GPI deacylase
                               HSD17B7      0.93          2.65    2.47   0.002     Hydroxysteroid (17-beta) dehydrogenase 7
                               TRIP10       1.05          2.63    2.75   \<0.001   Thyroid hormone receptor interactor 10
                               FDFT1        0.92          2.62    2.41   \<0.001   Farnesyl-diphosphate farnesyltransferase 1

Fold change was calculated as the mean of triplicate experiments.

###### 

Genes with downregulated expression (≥ 2.5-fold) following exposure of peripheral blood mononuclar cells to *Mycobacterium bovis*.

                                          Fold change                               
  ---------------------------- ---------- ------------- -------- -------- --------- ------------------------------------------------------------------------------
  Signal transduction                                                               
                               THBS1      1.33          −27.82   −20.91   \<0.001   Thrombospondin 1
                               HMOX1      1.29          −10.11   −7.86    \<0.001   Heme oxygenase (decycling) 1
                               FST        1.19          −7.82    −6.59    \<0.001   Follistatin
                               FOSL1      −1.08         −5.65    −6.11    0.004     Fos-related antigen 1 (FRA-1)
                               CD38       1.05          −5.64    −5.38    0.002     CD38 molecule
                               GNG4       1.06          −5.21    −4.93    \<0.001   Guanine nucleotide binding protein (G protein), gamma 4
                               FZD4       1.20          −4.98    −4.16    \<0.001   Frizzled homolog 4
                               EDN1       −1.14         −4.51    −5.13    0.002     Endothelin 1
                               PTAFR      1.14          −4.01    −3.51    0.005     Platelet-activating factor receptor
                               MRAS       1.29          −3.64    −2.82    0.002     Muscle RAS oncogene homolog
                               FOS        −1.02         −3.56    −3.64    0.002     FBJ murine osteosarcoma viral oncogene homolog
                               ICOS       −1.30         −3.06    −3.99    \<0.001   Inducible T-cell co-stimulator
                               FN1        1.20          −2.87    −2.40    0.004     Fibronectin 1
                               NUMBL      1.24          −2.83    −2.28    0.002     Numb homolog (Drosophila)-like
                               CACNG4     1.25          −2.79    −2.24    0.001     Calcium channel, voltage-dependent, gamma subunit 4
                               PTGS2      −1.13         −2.71    −3.06    \<0.001   Prostaglandin-endoperoxide synthase 2
                               TCF7L2     1.21          −2.51    −2.08    \<0.001   Transcription factor 7-like 2 (T-cell specific, HMG-box)
  Immune system                                                                     
                               C1QB       1.21          −26.31   −21.76   0.002     Complement component 1, q subcomponent, B chain
                               PPBP       −1.07         −17.11   −18.37   \<0.001   Pro-platelet basic protein (chemokine (C-X-C motif) ligand 7)
                               CFB        −1.07         −16.33   −17.52   \<0.001   Complement factor B (CFB)
                               IFNG       1.02          −14.28   −14.06   \<0.001   Interferon, gamma
                               THBD       −1.00         −14.27   −14.32   \<0.001   Thrombomodulin
                               GZMB       1.13          −9.25    −8.21    \<0.001   Granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1)
                               C1QA       1.08          −7.58    −7.03    \<0.001   Complement component 1, q subcomponent, A chain
                               SPP1       −1.07         −6.62    −7.05    0.003     Secreted phosphoprotein 1
                               PLK3       −1.10         −5.99    −6.60    \<0.001   Polo-like kinase 3 (Drosophila)
                               F13A1      1.07          −5.12    −4.79    0.002     Coagulation factor XIII, A1 polypeptide
                               PLA2G4A    1.07          −4.58    −4.28    0.002     Phospholipase A2, group IVA (cytosolic, calcium-dependent)
                               CD55       −1.09         −4.54    −4.97    \<0.001   CD55 molecule, decay accelerating factor for complement (Cromer blood group)
                               CD14       1.49          −4.41    −2.96    \<0.001   CD14 molecule
                               IL10       −1.29         −4.11    5.30     0.002     Interleukin 10
                               MAP3K8     −1.17         −4.02    −4.70    \<0.001   Mitogen-activated protein kinase kinase kinase 8
                               CCR3       1.01          −3.88    −3.84    0.003     Chemokine (C-C motif) receptor 3
                               CCR4       −1.06         −3.63    −3.85    0.002     Chemokine (C-C motif) receptor 4
                               KLRK1      −1.16         −3.55    −4.12    \<0.001   Killer cell lectin-like receptor subfamily K, member 1
                               IL2RA      −1.00         −3.46    −3.48    \<0.001   Interleukin 2 receptor, alpha (IL2RA)
                               CSF1R      1.32          −3.41    −2.58    \<0.001   Colony stimulating factor 1 receptor precursor
                               CCR1       1.08          −3.18    −2.95    0.003     Chemokine (C-C motif) receptor 1
                               CCL4       −1.06         −3.13    −3.31    0.006     Chemokine (C-C motif) ligand 4 (CCL4),
                               INHBA      1.04          −3.13    −3.02    0.002     Inhibin, beta A
                               PECAM1     1.04          −3.59    −3.47    0.001     Platelet/endothelial cell adhesion molecule
                               TNFRSF25   −1.10         −3.08    −3.40    \<0.001   Tumor necrosis factor receptor superfamily, member 25
                               CCL3       1.35          −3.01    −2.22    0.002     Chemokine (C-C motif) ligand 3
                               TLR8       −1.26         −2.85    −3.60    0.006     Toll-like receptor 8
                               IL12B      −1.20         −2.83    −3.40    0.004     Interleukin 12B
                               CTSB       −1.06         −2.79    −2.97    0.003     Cathepsin B
                               JAM3       1.05          −2.67    −2.54    \<0.001   Junctional adhesion molecule 3
                               SIPA1      1.07          −2.61    −2.43    0.003     Signal-induced proliferation-associated 1
                               PGD        −1.16         −2.54    −2.95    0.004     Phosphogluconate dehydrogenase
  Endocytosis and transport                                                         
                               RAB7B      1.13          −4.29    −3.79    \<0.001   RAB7B, member RAS oncogene family
                               CD36       1.02          −3.58    −3.50    0.001     CD36 molecule (thrombospondin receptor)
                               ACP2       1.00          −3.56    −3.54    \<0.001   Acid phosphatase 2, lysosomal
                               SORT1      −1.02         −3.45    −3.51    \<0.001   Sortilin 1
                               ACTB       1.17          −2.85    −2.44    \<0.001   Actin, beta
                               AP1B1      1.03          −2.78    −2.71    \<0.001   Adaptor-related protein complex 1, beta 1 subunit
  Inflammation and apoptosis                                                        
                               TNF        −1.02         −6.07    −6.18    \<0.001   Tumor necrosis factor (TNF superfamily, member 2)
                               IL1RAP     1.17          −4.85    −5.67    0.005     Interleukin 1 receptor accessory protein
                               IGFBP3     −1.06         −3.06    −3.23    0.002     Insulin-like growth factor binding protein 3
                               CDKN1C     1.33          −2.95    −2.22    \<0.001   Cyclin-dependent kinase inhibitor 1C (p57, Kip2)
                               AMOTL1     −1.10         −2.71    −2.99    0.001     Angiomotin like 1
                               FASLG      −1.19         −2.62    3.12     \<0.001   Fas ligand
  Others                                                                            
                               CYP3A4     −1.04         −4.65    −4.83    0.002     Cytochrome P450, subfamily IIIA, polypeptide 4
                               B4GALT6    −1.05         −4.09    −4.31    0.003     B4GALT6 protein, transcript variant 2
                               TBXAS1     1.07          −4.03    −3.78    0.002     Thromboxane A synthase 1
                               ST8SIA1    1.07          −3.78    3.52     0.002     Alpha-N-acetylneuraminide alpha-2,8-sialyltransferase
                               GAB1       1.29          −3.61    −4.65    \<0.001   GRB2-associated binding protein 1
                               HSD17B8    1.01          −3.60    −3.57    0.005     Hydroxysteroid (17-beta) dehydrogenase 8
                               HS3ST1     1.55          −3.27    −2.11    0.001     Heparan sulfate (glucosamine) 3-O-sulfotransferase 1
                               MMP14      1.04          −3.09    −2.96    \<0.001   Matrix metallopeptidase 14
                               ITGAD      1.03          −2.83    −2.75    \<0.001   Integrin, alpha D
                               TXNDC5     −1.08         −3.34    −3.60    \<0.001   Thioredoxin domain-containing protein 5 precursor
                               VIM        1.06          −2.59    −2.44    0.004     Vimentin
                               SDS        −1.23         −3.93    −4.85    \<0.001   Serine dehydratase
                               EME2       1.09          −2.65    2.44     0.003     Endonuclease
                               SFRS7      −1.02         −2.82    −2.87    \<0.001   Splicing factor, arginine/serine-rich 7
                               NUP160     1.15          −3.01    −2.62    0.001     Nucleoporin 160kDa
                               PWP2       1.13          −2.92    −2.59    \<0.001   Periodic tryptophan protein 2 homolog
                               DSE        −1.09         −2.92    −3.17    \<0.001   Dermatan sulfate epimerase
                               PNPLA4     1.10          −2.83    −2.57    \<0.001   Patatin-like phospholipase domain containing 4
                               BLVRB      1.00          −2.75    −2.75    \<0.001   Biliverdin reductase B
                               CHST2      1.04          −2.75    −2.64    \<0.001   Carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2
                               AGPAT3     1.08          −2.63    −2.43    \<0.001   1-acylglycerol-3-phosphate O-acyltransferase 3
                               EXT1       −1.19         −2.61    −3.12    0.001     Exostoses (multiple) 1
                               GSTK1      1.12          −2.60    −2.90    0.002     Glutathione S-transferase kappa 1

Fold change was calculated as the mean of triplicate experiments.

###### 

Ingenuity pathway analysis profile of genes differentially expressed between 0 and 4 hours post-infection with *Mycobacterium bovis*.

  Symbol   Entrez gene name                                                                          Fold change   Network   Location              Type(s)
  -------- ----------------------------------------------------------------------------------------- ------------- --------- --------------------- -------------------------
  CLDN3    Claudin 3                                                                                 3.07          3         Plasma membrane       Transmembrane receptor
  MMP2     Matrix metallopeptidase 2 (gelatinase A, 72 kDa gelatinase, 72 kDa type IV collagenase)   0.11          3         Extracellular space   Peptidase
  MAPK14   Mitogen-activated protein kinase 14                                                       0.05          1         Cytoplasm             Kinase
  GEMIN6   Gem (nuclear organelle) associated protein 6                                              −0.09         4         Nucleus               Other
  TNF      Tumor necrosis factor                                                                     −0.09         1         Extracellular space   Cytokine
  TGFB1    Transforming growth factor, beta 1                                                        −0.13         1         Extracellular space   Growth factor
  CREB1    cAMP responsive element binding protein 1                                                 −0.51                   Nucleus               Transcription regulator
  IL1B     Interleukin 1, beta                                                                       −0.52         1         Extracellular space   Cytokine
  STRAP    Serine/threonine kinase receptor associated protein                                       −0.60         4         Plasma membrane       Other
  REM1     RAS (RAD and GEM)-like GTP-binding 1                                                      −3.13                   Other                 Enzyme
  MMP13    Matrix metallopeptidase 13 (collagenase 3)                                                −6.25         1         Extracellular space   Peptidase
  ADCY6    Adenylate cyclase 6                                                                       −6.67         2         Plasma membrane       Enzyme
  GEMIN7   Gem (nuclear organelle) associated protein 7                                              −11.11        4         Nucleus               Other
  SMURF2   SMAD specific E3 ubiquitin protein ligase 2                                               −16.67        1         Cytoplasm             Enzyme
  FMO4     Flavin containing monooxygenase 4                                                         −32.98                  Cytoplasm             Enzyme

###### 

Pathways involving genes differentially expressed between 0 and 4 hours post-infection with *Mycobacterium bovis*.

  Ingenuity canonical pathway                    \|−log (p)\|   Gene ratio^[a](#tfn3-etm-0-0-2814){ref-type="table-fn"}^   Genes
  ---------------------------------------------- -------------- ---------------------------------------------------------- --------------
  Granulocyte adhesion and diapedesis            2.57           1.2E-02                                                    MMP13, CLDN3
  Agranulocyte adhesion and diapedesis           2.52           1.14E-02                                                   MMP13, CLDN3
  Leukocyte extravasation signaling              2.43           1.02E-02                                                   MMP13, CLDN3
  Oncostatin M signaling                         1.78           2.94E-02                                                   MMP13
  Inhibition of matrix metalloproteases          1.73           2.63E-02                                                   MMP13
  CDK5 signaling                                 1.38           1.12E-02                                                   ADCY6
  TGF-β signaling                                1.38           1.08E-02                                                   SMURF2
  IL-1 signaling                                 1.36           9.8E-03                                                    ADCY6
  HIF1α signaling                                1.32           9.8E-03                                                    MMP13
  Gαi signaling                                  1.24           7.81E-03                                                   ADCY6
  eNOS signaling                                 1.23           7.75E-03                                                   ADCY6
  CXCR4 signaling                                1.15           6.25E-03                                                   ADCY6
  Gap junction signaling                         1.15           6.41E-03                                                   ADCY6
  Tight junction signaling                       1.14           6.37E-03                                                   CLDN3
  PPARα/RXRα activation                          1.11           5.75E-03                                                   ADCY6
  RAR activation                                 1.09           5.59E-03                                                   ADCY6
  LPS/IL-1 mediated inhibition of RXR function   1.01           4.5E-03                                                    FMO4

Number of pathway genes differentially expressed/number of genes in pathway.

###### 

Ingenuity pathway analysis profile of genes differentially expressed between 0 and 24 hours post-infection with *Mycobacterium bovis*.

  Symbol   Entrez gene name                                                               Fold change   Network   Location              Type(s)
  -------- ------------------------------------------------------------------------------ ------------- --------- --------------------- ----------------------------
  GPNMB    Glycoprotein (transmembrane) nmb                                               22.93         2         Plasma membrane       Enzyme
  AK4      Adenylate kinase 4                                                             19.13         4         Cytoplasm             Kinase
  KCNH2    Potassium voltage-gated channel, subfamily H (eag-related), member 2           18.27         4         Plasma membrane       Ion channel
  CLEC4E   C-type lectin domain family 4, member E                                        13.36         2         Plasma membrane       Other
  CLU      Clusterin                                                                      12.13         4         Cytoplasm             Other
  C3AR1    Complement component 3a receptor 1                                             7.93          1         Plasma membrane       G-protein coupled receptor
  Akt      Bos taurus v-akt murine thymoma viral oncogene homolog 2                       2.06          4         Cytoplasm             Group
  BCL2     B-cell CLL/lymphoma 2                                                          −0.29         3         Cytoplasm             Transporter
  CASP8    Caspase 8, apoptosis-related cysteine peptidase                                −0.60                   Nucleus               Peptidase
  NFKB1    Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1           −0.80                   Nucleus               Transcription regulator
  IL1B     Interleukin 1, beta                                                            −1.04                   Extracellular space   Cytokine
  FCER1G   Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide           −1.98                   Plasma membrane       Transmembrane receptor
  CD55     CD55 molecule, decay accelerating factor for complement (Cromer blood group)   −4.76         2         Plasma membrane       Other
  TNF      Tumor necrosis factor                                                          −6.45         1         Extracellular space   Cytokine
  C1QA     Complement component 1, q subcomponent, A chain                                −7.69         1         Extracellular space   Other
  PLK3     Polo-like kinase 3                                                             −8.33         3         Nucleus               Kinase
  CEBPD    CCAAT/enhancer binding protein (C/EBP), delta                                  −9.09         4         Nucleus               Transcription regulator
  IL17F    Interleukin 17F                                                                −9.52         1         Extracellular space   Cytokine
  GZMB     Granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1)   −11.11        1         Cytoplasm             Peptidase
  MMP13    Matrix metallopeptidase 13 (collagenase 3)                                     −11.11        1         Extracellular space   Peptidase
  SMURF2   SMAD specific E3 ubiquitin protein ligase 2                                    −12.50        3         Cytoplasm             Enzyme
  CFB      Complement factor B                                                            −13.33        1         Extracellular space   Peptidase
  THBS1    Thrombospondin 1                                                               −13.33        1,2       Extracellular space   Other
  FMO4     Flavin containing monooxygenase 4                                              −14.29                  Cytoplasm             Enzyme
  IFNG     Interferon, gamma                                                              −20.00        1,3       Extracellular space   Cytokine
  THBD     Thrombomodulin                                                                 −20.00        1         Plasma membrane       Transmembrane receptor
  IL17RB   Interleukin 17 receptor B                                                      −25.00        1         Plasma membrane       Transmembrane receptor
  C1QB     Complement component 1, q subcomponent, B chain                                −28.57        1         Extracellular space   Other

###### 

Pathways involving genes differentially expressed between 0 and 24 hours post-infection with *Mycobacterium bovis*.

  Ingenuity canonical pathways                                            \|-log (P)\|   Gene ratio^[a](#tfn4-etm-0-0-2814){ref-type="table-fn"}^   Molecules
  ----------------------------------------------------------------------- -------------- ---------------------------------------------------------- ------------------------------
  Pattern recognition receptors in recognition of bacteria and viruses    3.23E00        4.21E-02                                                   C1QA, C1QB, C3AR1, TNF
  Production of nitric oxide and reactive oxygen species in macrophages   3.02E00        2.69E-02                                                   IFNG, MAP3K8, TNF, CLU, RBP4
  Cytokines mediating communication between immune cells                  2.86E00        5.77E-02                                                   IFNG, IL17F, TNF
  T helper cell differentiation                                           2.55E00        4.35E-02                                                   IFNG, IL17F, TNF
  VDR/RXR activation                                                      2.37E00        3.85E-02                                                   IFNG, SPP1, THBD
  Crosstalk between dendritic cells and natural killer cells              2.2E00         3.3E-02                                                    IFNG, TNF, ACTG1
  Acute phase response signaling                                          1.47E00        1.73E-02                                                   CFB, TNF, RBP4
  Communication between innate and adaptive immune cells                  1.33E00        2.15E-02                                                   IFNG, TNF
  PI3K/AKT signaling                                                      1.03E00        1.48E-02                                                   GAB1, MAP3K8
  TNFR2 signaling                                                         9.51E-01       3.12E-02                                                   TNF
  Interferon signaling                                                    8.72E-01       2.94E-02                                                   IFNG
  Antigen presentation pathway                                            8.38E-01       2.5E-02                                                    IFNG
  Inhibition of matrix metalloproteases                                   8.28E-01       2.63E-02                                                   MMP13
  NF-κB signaling                                                         7.96E-01       1.14E-02                                                   MAP3K8, TNF
  iNOS signaling                                                          7.78E-01       2.13E-02                                                   IFNG
  TNFR1 signaling                                                         7.43E-01       1.96E-02                                                   TNF
  Cytotoxic T lymphocyte-mediated apoptosis of target cells               7.27E-01       1.92E-02                                                   GZMB
  Leukocyte extravasation signaling                                       7.08E-01       1.02E-02                                                   MMP13, ACTG1
  Death receptor signaling                                                6.62E-01       1.61E-02                                                   TNF
  Activation of IRF by cytosolic pattern recognition receptors            6.49E-01       1.59E-02                                                   TNF
  Role of PI3K/AKT signaling in the pathogenesis of influenza             6.42E-01       1.49E-02                                                   IFNG
  IL-10 signaling                                                         6.01E-01       1.39E-02                                                   TNF
  Apoptosis signaling                                                     5.06E-01       1.09E-02                                                   TNF
  Fcγ receptor-mediated phagocytosis in macrophages and monocytes         4.87E-01       1.05E-02                                                   ACTG1

Number of pathway genes differentially expressed/number of genes in pathway.
